Clinical practice guideline for breast fibroadenoma: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021  

作　　者：Yuan Peng Fei Xie Yi Zhao Shu Wang Chinese Society of Breast Surgery 

机构地区：[1]Department of Breast Center,Peking University People’s Hospital,Beijing 100044,China [2]Department of Oncology,Shengjing Hospital of China Medical University,Shenyang,Liaoning 110022,China [3]不详

出　　处：《Chinese Medical Journal》2021年第9期1014-1016,共3页中华医学杂志（英文版）

摘　　要：Breast fibroadenoma is the most common benign tumor of the breast in women,and can occur at all ages.However,these tumors are more commonly seen in women aged 15 to 35 years.[1]Most fibroadenomas often undergo self-limited growth and usually stabilize after several years.The clinical diagnosis is mainly based on clinical palpation and ultrasonographic examination,while the golden standard diagnosis is pathological examination.To standardize the clinical diagnosis and treatment of breast fibroadenoma,the Chinese Society of Breast Surgery(CSBrS)conducted a literature review of experts’opinions,and determined the key clinical questions for the clinical practice guideline of breast fibroadenoma.The group evaluated the relevant evidences using the grading of recommendations assessment,development,and evaluation system,and developed the clinical practice guideline for breast fibroadenoma:CSBrS practice guideline 2021,with the aim of providing clinical practice guidance to breast surgeons in China.

关 键 词：SURGERY FIBROADENOMA DIAGNOSIS 

分 类 号：R737.9[医药卫生—肿瘤]